SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

This study is a randomized, open-label, controlled, multicenter phase Ⅲ clinical trial, which aims to evaluate the efficacy and safety of SYS6002 versus investigator's choice of chemotherapy in the treatment of participants with recurrent or metastatic cervical cancer who have failed platinum-containing chemotherapy and PD-1/L1 inhibitor therapy

NCT Number	NCT07230626
Lead Sponsor	CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions	Cervical Cancer
Enrollment	412 participants
Start Date	2025-11-20
Primary Completion	2028-01-01 (estimated)
Study Completion	2028-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-11-17